1. Introduction {#sec1}
===============

Intracerebral hemorrhage (ICH) is a disease with high morbidity and mortality [@bib1]. Diabetes mellitus (DM) is an established risk factor for ischemic stroke. However, very few studies have shown that DM and admission hyperglycemia is associated with poor outcome in ICH patients \[[@bib2], [@bib3]\]. In many prior studies, diabetes and glycemic status was ascertained only by past medical history [@bib4], or by admission glucose levels which were probably influenced by the acute stress response that accompanies ICH. Hemoglobin (Hb) A1c remains the best screening tool to diagnose prediabetes and diabetes while taking into account the glucose fluctuations in such acute events [@bib5]. However, very few studies have examined the relationship between HbA1c and outcomes in ICH patients \[[@bib6], [@bib7]\].

Utilizing HbA1c as the marker of glycemic control and data from the Get with The Guidelines (GWTG) Stroke registry, we hypothesized that poor hyperglycemic control is associated with worst clinical outcomes in ICH patients.

2. Materials and methods {#sec2}
========================

2.1. Data source {#sec2.1}
----------------

GWTG-Stroke is an ongoing, voluntary, continuous registry, and performance improvement initiative in stroke care. It has been collected since 2003 by the Quintiles Company (Cambridge, MA) and analyzed by Duke Clinical Research Institute (DCRI) (Durham, NC). The details of the GWTG-stroke registry data collection and definitions methods have been described before \[[@bib8], [@bib9], [@bib10]\]. In brief, the data is de-identified at patient collection level by the participating sites, while following local regulations and privacy laws, with local IRB approval obtained as required. The Duke IRB approved the data analysis by DCRI.

2.2. Primary and secondary outcomes {#sec2.2}
-----------------------------------

The primary outcome of interest was in-hospital mortality and secondary outcomes of interest were discharge disposition, ambulatory status and modified Rankin Scale (mRS). We compared outcomes of interest in ICH patients across the different HbA1c groups, stratified by history of diabetes mellitus.

2.3. Study population {#sec2.3}
---------------------

The study population was limited to patients diagnosed with ICH in fully participating sites in the GWTG-stroke registry from April 1, 2003 to September 30, 2015. Patients with missing HbA1c, lack of hemorrhage on first CT, missing medical history or discharge disposition were excluded from the analysis.

2.4. Statistical analysis {#sec2.4}
-------------------------

For the study analysis, the patients with recorded HbA1c values were divided into four ordinal categories: HbA1c less than 5.7%, HbA1c 5.7--6.4%, HbA1c 6.5--8.0% and HbA1c \> 8.0%.

The study population was further split into diabetics (prior history of diabetes mellitus and/or documented use of anti-diabetic medications on admission) and non-diabetics (no prior history of diabetes mellitus/no prior use of anti-diabetic medications). This non-diabetic group had potential to include patients who were undiagnosed diabetes mellitus. However, this group was also unique because none of these patients were exposed to any diabetic medications and hence their HbA1c values were true estimates of their overall glycemic status. Hence, patients with HbA1c ranging between 5.7-6.4% were considered true prediabetes patients.

To compare patient characteristics, and outcomes of interest, categorical variables were presented as counts and proportions, and differences between groups were tested using Kruskal-Wallis test. Continuous variables were presented as medians with interquartile ranges (IQR), and difference between groups was tested based on the Spearman rank correlation coefficient. Statistically significant increasing or decreasing trend in the distribution of the row variables across HbA1c groups in the ICH population were indicated by p-values less than 0.05.

Unadjusted and adjusted multivariable logistic regression models with generalized estimating equations (GEE) were used to assess the associations between HbA1c groups and the outcomes of interests, after accounting for within-hospital clustering. Diabetes history and its interaction with HbA1c groups were included in both unadjusted and adjusted models. Adjusted models also accounted for the potential confounding covariates, including demographics (age, gender, race), medical history (Atrial fib/flutter, previous stroke/TIA, CAD/prior MI, heart failure, carotid stenosis, diabetes, PVD, hypertension, dyslipidemia, smoking), arrival via EMS, on-hour arrival, and hospital characteristics (region, teaching status, number of beds, annual ICH volume, rural location, primary stroke center, comprehensive stroke center) (Supplemental Table I). For any patient variables with missing rate lower than 20%, multiple imputations with 25 imputed datasets were used (Supplemental Table II). Linearity of continuous covariates was assessed and transformations or splines were applied when appropriate. Odds ratios (OR) for each binary outcome were reported, with normal range HbA1c (value less than 5.7%) as the reference group. If the interaction p-value is less than 0.05, it suggests that the association between HbA1c groups and the outcome differs significantly by diabetes history. Other p-values less than 0.05 indicate the OR is significantly different from 1. Since many patients had missing NIHSS on admission, a subset analysis was performed on patients who had admission NIHSS score available. All tests were 2-tailed with a level of statistical significance of p \< 0.05. Statistical analyses were performed using SAS version 9.4 software (SAS Institute Inc, Cary, NC).

3. Results {#sec3}
==========

3.1. Characteristics of study population {#sec3.1}
----------------------------------------

Among 372,822 ICH patients from 2,007 sites, 287,653 patients were excluded due to missing HbA1c data, 6,908 patients were excluded due to lack of hemorrhage on first scan, 2,755 patients were excluded due to being transferred out, leaving against medical advice (AMA), lacking discharge disposition or otherwise unable to determine and 51 patients were excluded due to missing medical history. Our final study population was 75,455 patients from 1,336 sites.

When compared to patients with missing HbA1c values, the study population had lower initial NIHSS score, in-hospital mortality and mRS at discharge but significantly higher median blood glucose ([Table 1](#tbl1){ref-type="table"}).Table 1Baseline characteristics by Hba1c missing status.Table 1VariableHbA1c missingHbA1c not missingP-valueN = 213,220N = 75,455**Patient demographics**Age72 (58--82)67 (56--78)\<.001Gender, Female50.0944.88\<.001Race/Ethnicity White68.2957.68\<.001 Black15.2122.73**Measurements**Weight90 (69--141)91 (72--139)\<.001BMI25.9 (22.6--30.1)27.5 (23.8--32.3)\<.001HbA1C (0--20), %NA5.9 (5.5--6.7)-SBP (50--250), mm Hg160 (139--186)163 (143--189)\<.001DBP (20--200), mm Hg85 (72--100)88 (74--104)\<.001Blood glucose (20--800), mg/dL129 (106--165)134 (109--177)\<.001**Medical history**Atrial fibrillation/flutter16.2612.88\<.001CAD/Prior MI19.5418.45\<.001Carotid stenosis1.831.740.112Diabetes mellitus20.7236.24\<.001Peripheral vascular disease (PVD)3.273.01\<.001Hypertension71.7777.82\<.001Smoker13.2115.49\<.001Dyslipidemia29.8632.71\<.001Heart failure5.345.68\<.001Prior stroke/TIA24.6123.87\<.001Chronic renal insufficiency2.032.99\<.001**Medications prior to admission**Antiplatelets36.1835.520.005Anticoagulants20.8615.87\<.001Cholesterol-reducers32.0133.85\<.001Diabetic medications15.2626.60\<.001**Arrival information**Arrival mode: EMS59.8749.59\<.001On-hour arrival (non-holiday, weekday, 7a-6p)40.5238.83\<.001Ambulatory status at admission Able to ambulate independently17.6320.40\<.001 With assistance from person13.7817.76 Unable to ambulate68.5861.85NIHSS recorded40.5257.77\<.001Initial NIHSS score (0--42)10 (3--21)8 (3--17)\<.001**Hospital characteristics**Primary stroke center56.6558.27\<.001Comprehensive stroke center17.9123.33\<.001Academic/Teaching hospital69.7975.49\<.001Rural Location2.611.52\<.001Region West20.4519.24\<.001 South35.2537.73 Midwest19.5820.73 Northeast24.7222.29Number of Beds425 (301--612)474 (342--706)\<.001Annual Volume of ICH Admissions53 (29--89)63 (38--106)\<.001

[Table 2](#tbl2){ref-type="table"} demonstrated the baseline characteristics of the included patients. Prior history of diabetes was present in 36.2% of the overall cohort with increasing trend across the HBA1c groups. Given the large size of the cohort, we detected many statistically significant differences in the data, but these differences might not be clinically meaningful ([Table 2](#tbl2){ref-type="table"}).Table 2Comparison of baseline patient characteristics across Hba1c Groups.Table 2VariableHbA1c \<5.7% (N = 25473)HbA1c 5.7--6.5% (N = 26815)HbA1c 6.5--8.0% (N = 14317)(HbA1c \>8.0% (N = 8850)P-value*Age*64 (53--77)70 (58--80)69 (59--78)62 (54--72)\<.0001Female11434 (44.9)12681 (47.3)6117 (42.7)3629 (41.0)\<.0001*Ethnicity* White15422 (60.6)15758 (58.8)8079 (56.4)4243 (48.0)\<.0001 Black5786 (22.7)5946 (22.2)3126 (21.8)2289 (25.9)Weight85 (68--130)90 (71--136)97 (77--148)101 (79--158)\<.0001BMI26.0 (22.7--30.2)27.4 (23.8--32.0)29.2 (25.3--34.3)30.0 (25.8--35.3)\<.0001HbA1C (0--20), %5.3 (5.1--5.5)6.0 (5.8--6.2)7.0 (6.7--7.4)9.5 (8.6--10.9)\<.0001SBP (50--250), mm Hg161 (141--188)164 (144--189)164 (144--190)168 (146--195)\<.0001DBP (20--200), mm Hg88 (75--105)88 (74--103)86 (73--102)90 (76--106)0.0026Blood glucose (20--800), mg/dL118 (102--143)127 (108--156)164 (132--210)254 (187--328)\<.0001Diabetes mellitus2852 (11.2)6761 (25.2)10248 (71.6)7486 (84.6)\<.0001Hypertension18033 (70.8)20871 (77.8)12226 (85.4)7591 (85.8)\<.0001Chronic renal insufficiency768 (3.0)587 (2.2)534 (3.7)366 (4.1)\<.0001Antiplatelet6106 (28.8)7662 (36.0)4986 (45.3)2711 (39.1)\<.0001Anticoagulants2302 (11.9)3341 (17.3)2045 (21.2)933 (15.3)\<.0001Cholesterol-reducers5981 (23.5)9248 (34.5)6693 (46.8)3603 (40.7)\<.0001Anti-Diabetic1514 (6.0)4508 (17.0)8082 (57.0)5759 (65.7)\<.0001*PreICH ambulatory status* Able to ambulate independently3354 (20.5)3361 (20.1)1745 (20.0)1196 (21.8)\<.0001 With assistance from person2708 (16.5)3008 (17.9)1624 (18.6)1066 (19.4) Unable to ambulate10320 (63.0)10393 (62.0)5343 (61.3)3223 (58.8)*Initial NIHSS score (0--42)*8 (3--17)8 (3--17)7 (2--16)7 (2--17)\<.0001[^1]

3.2. Hemoglobin A1c and overall clinical outcome {#sec3.2}
------------------------------------------------

Overall, patients with HbA1c \>8% had 13.5% mortality as compared to patients with HbA1c 6.5--8.0% (13.6%), HbA1c 5.7--6.5% (14%), and HbA1c\<5.7% (15%). A similar trend was observed in discharge disposition - higher hemoglobin A1c \>8.0% was associated with higher rates of discharge to home and/or independent ambulatory status when compared to other HbA1c groups ([Table 3](#tbl3){ref-type="table"}).Table 3Comparison of outcomes in ICH patients across Hba1c Groups.Table 3VariablePrior diabetes(HbA1c \<5.7%) (N = 25473)(HbA1c 5.7--6.5%) (N = 26815)(HbA1c 6.5--8.0%) (N = 14317)(HbA1c \>8.0%) (N = 8850)*In-hospital mortality*All3947 (15.5)3762 (14.0)1950 (13.6)1199 (13.5)Yes542 (19)1016 (15.03)1399 (13.65)994 (13.28)No3405 (15.05)2746 (13.69)551 (13.54)205 (15.03)*Discharged* homeAll7353 (34.2)7256 (31.5)3960 (32.0)2845 (37.2)Yes644 (27.88)1664 (28.96)2751 (31.09)2417 (37.23)No6709 (34.91)5592 (32.31)1209 (34.37)428 (36.93)*Discharge independent ambulatory status*All6958 (29.1)6995 (27.9)3756 (28.0)2599 (31.3)Yes577 (21.78)1574 (24.95)2627 (27.27)2198 (31.41)No6381 (30.06)5421 (28.89)1129 (29.69)401 (30.99)*Discharge mRS*All4 (3--6)4 (3--5)4 (3--5)4 (3--6)Yes5 (4--6)4 (3--6)4 (3--5)4 (3--5)No4 (3--5)4 (3--5)4 (3--6)4 (3--6)

3.3. Clinical outcomes in diabetics (prior history of DM or use of anti-diabetic medications on admission) {#sec3.3}
----------------------------------------------------------------------------------------------------------

When we analyzed patients with prior medical history of diabetes, patients with HbA1c \>8% had 13.5% mortality as compared to patients with HbA1c 6.5--8.0% (13.3%), HbA1c 5.7--6.5% (15%), and HbA1c\<5.7% (19%). Higher HbA1c \>8% was also associated with higher rates of discharge to home and/or independent ambulatory status and lower scores on modified Rankin Scale (mRS) at discharge when compared to other HbA1c groups ([Table 3](#tbl3){ref-type="table"}).

When patients with abnormal HbA1c and prior history of DM were compared to patients with reference HbA1c \<5.7% in a multivariate model, there was an overall lower in-hospital mortality, increased chances of going home and lower mRS, across all other ranges of HbA1c ([Table 4](#tbl4){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}).Table 4Adjusted associations between Hba1c Groups and outcomes without adjusting for NIHSS.Table 4OutcomesPrior diabetesHbA1c groupsAdjusted*Dichotomized*OR (95% CI)P-valueIn-hospital mortalityInteraction p-value (3df)0.0048YesHbA1c \>8.0%0.70 (0.62--0.80)\<.0001HbA1c 6.5--8.0%0.71 (0.62--0.80)\<.0001HbA1c 5.7--6.5%0.79 (0.69--0.90)0.0004HbA1c \<5.7%Reference-NoHbA1c \>8.0%1.00 (0.84--1.19)0.9755HbA1c 6.5--8.0%0.88 (0.79--0.98)0.0222HbA1c 5.7--6.5%0.91 (0.85--0.97)0.0027HbA1c \<5.7%Reference-Discharged homeInteraction p-value (3df)0.0161YesHbA1c \>8.0%1.27 (1.12--1.44)0.0002HbA1c 6.5--8.0%1.21 (1.07--1.36)0.0016HbA1c 5.7--6.5%1.11 (0.99--1.25)0.0718HbA1c \<5.7%Reference-NoHbA1c \>8.0%0.95 (0.84--1.09)0.4744HbA1c 6.5--8.0%1.04 (0.96--1.13)0.3492HbA1c 5.7--6.5%1.01 (0.96--1.05)0.8164HbA1c \<5.7%Reference-Modified Rankin scale at discharge (0--2 vs 3--6)Interaction p-value (3df)0.0003YesHbA1c \>8.0%1.62 (1.30--2.02)\<.0001HbA1c 6.5--8.0%1.55 (1.24--1.93)0.0001HbA1c 5.7--6.5%1.33 (1.06--1.66)0.0149HbA1c \<5.7%Reference-NoHbA1c \>8.0%0.89 (0.71--1.12)0.3378HbA1c 6.5--8.0%0.96 (0.83--1.11)0.5576HbA1c 5.7--6.5%1.04 (0.96--1.14)0.3522HbA1c \<5.7%Reference-Fig. 1Forest plot depicting unadjusted and adjusted outcomes across the dichotomized groups when compared to reference (Hba1c \< 5.7%).Fig. 1

When we performed a subset analysis in patients with available NIHSS and adjusted for admission severity, there continued to be lower mortality associated with higher hemoglobin A1c values in diabetic population ([Table 5](#tbl5){ref-type="table"}).Table 5Adjusted associations between Hba1c Groups and outcomes adjusted for NIHSS among NIHSS non-missing population only.Table 5OutcomesPrior diabetesHbA1c groupsAdjusted*Dichotomized*OR (95% CI)P-valueIn-hospital mortalityInteraction p-value (3df)0.1151YesHbA1c \>8.0%0.78 (0.65--0.93)0.0070HbA1c 6.5--8.0%0.73 (0.62--0.87)0.0004HbA1c 5.7--6.5%0.72 (0.60--0.87)0.0006HbA1c \<5.7%Reference-NoHbA1c \>8.0%0.97 (0.75--1.26)0.8463HbA1c 6.5--8.0%0.88 (0.74--1.05)0.1548HbA1c 5.7--6.5%0.92 (0.84--1.01)0.0690HbA1c \<5.7%Reference-Discharged homeInteraction p-value (3df)0.6352YesHbA1c \>8.0%1.04 (0.86--1.25)0.6928HbA1c 6.5--8.0%1.05 (0.88--1.25)0.5969HbA1c 5.7--6.5%1.00 (0.83--1.19)0.9629HbA1c \<5.7%Reference-NoHbA1c \>8.0%0.94 (0.78--1.15)0.5662HbA1c 6.5--8.0%1.12 (1.00--1.25)0.0521HbA1c 5.7--6.5%0.99 (0.93--1.07)0.8759HbA1c \<5.7%Reference-Modified Rankin scale at discharge (0--2 vs 3--6)Interaction p-value (3df)0.6540YesHbA1c \>8.0%1.28 (0.94--1.74)0.1150HbA1c 6.5--8.0%1.33 (0.98--1.81)0.0707HbA1c 5.7--6.5%1.27 (0.91--1.78)0.1545HbA1c \<5.7%Reference-NoHbA1c \>8.0%1.05 (0.70--1.57)0.8258HbA1c 6.5--8.0%1.04 (0.85--1.27)0.7177HbA1c 5.7--6.5%1.10 (0.98--1.24)0.1099HbA1c \<5.7%Reference-

3.4. Clinical outcomes in non-diabetics (no prior history of DM nor prior use of anti-diabetic medications on admission) {#sec3.4}
------------------------------------------------------------------------------------------------------------------------

In patients with no prior history of DM, patients with HbA1c \>8% had 15.0% mortality as compared to patients with HbA1c 6.5--8.0% (13.5%), HbA1c 5.7--6.5% (13.7%), and HbA1c\<5.7% (15%). Rates of discharge to home, good ambulatory status and discharge mRS were comparable across all groups ([Table 3](#tbl3){ref-type="table"}).

In multivariate model, patients with HbA1c 5.7--6.5% and HbA1c 6.5--8.0% had significantly lower mortality than patients with HbA1c \<5.7%. However, mortality rates were similar in patients with HbA1c \> 8.0 and HbA1c \<5.7% ([Table 4](#tbl4){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}).

However, when the subset of patients with documented NIHSS were adjusted for admission injury severity; rates of mortality, discharge to home, independent ambulatory status and discharge mRS were similar across all groups ([Table 5](#tbl5){ref-type="table"}).

4. Discussion {#sec4}
=============

Our study showed that in patients with known history of DM or exposure to any diabetic treatment prior to admission, higher HbA1c groups (5.7--6.5%, 6.5--8.0% and \>8.0%) had lower mortality and better discharge outcomes when compared to lower HbA1c (\<5.7%). The most remarkable characteristic of the study population was the direct correlation of the increasing HbA1c values with higher BMI. This could be a potential confounder as patients with higher HbA1c had better outcomes and may be suggestive of the obesity paradox seen in other literature especially in Percutaneous Coronary Intervention (PCI), where obesity has been found to be protective of bleeding \[[@bib11], [@bib12], [@bib13]\].

The relationship of prior HbA1c and ICH prognosis has not been studied in large cohorts. Kazui et al. retrospectively reviewed the relationship of HbA1c and hematoma growth in 186 patients and found it to be directly associated with an interaction of fasting blood glucose (FBG) ≥141 mg/dL and systolic blood pressure (SBP) ≥200 mm Hg, and interaction of HbA1c ≥ 5.1% and SBP ≥200 mm Hg [@bib14]. Zhang et al. retrospectively reviewed 332 patients with ICH from a prospectively collected dataset and found a direct correlation between higher HbA1c and greater hematoma expansion and poor outcome specifically in diabetic patients [@bib7]. There are several studies showing poor outcome in ICH patients with poor admission glycemic state, though these studies were modest in size \[[@bib2], [@bib3], [@bib15], [@bib16], [@bib17]\]. This relationship holds true in animal models with possible mechanisms including hematoma expansion and worsening of peri-hematoma edema \[[@bib18], [@bib19], [@bib20]\]. However, this association becomes more complicated when groups are stratified according to prior clinical history of diabetes, which in most cases is underdiagnosed and may bias the results. Our study is unique as we tried to stratify groups based on their pre-stroke glycemic status (HbA1c), which is the true predictor of whether patient has diabetes, or not. The results of our study are contradictory to popular belief that higher HbA1c should always be associated with poor clinical outcome. One way to explain the discrepancy between our data and prior studies measuring admission hyperglycemia and ICH outcomes is that admission hyperglycemia may indicate a stress related response that is mostly unrelated to pre-ICH glycemic status. There has been suggestion in numerous studies that admission hyperglycemia and worsening outcome is more related to the initial injury severity and not the pre-morbid glycemic status of the patient [@bib21]. Acute stress hyperglycemia may in fact be beneficial for critically ill patients \[[@bib22], [@bib23]\]. Prior use of anti-diabetic medications may reduce this beneficial effect and contribute to mortality and morbidity.

Our study also suggested a trend towards poor outcome in patients with HbA1c\>8% without a prior diagnosis of diabetes. This finding suggests that absence of glycemic control does have some role to play in mortality and morbidity in ICH patients with undiagnosed diabetes. There is also a trend of higher mortality in patients with HbA1c \<5.7% in non-diabetic population who were not exposed to anti-diabetic medications. Patients with low HbA1c especially \<5.0% have been shown to have higher all-cause mortality in previously published literature and considered a generalized marker of mortality risk in general population [@bib24]. Additionally, a recent population-based study showed that low blood glucose was a risk factor for incident ICH [@bib25]. There is also a possible lack of stress response to insult in the group with low HbA1c [@bib26]. It is now clear why low HbA1c could be related to poor ICH outcome. Potential explanations include that low HbA1c has been associated with liver disease, low fibrinogen, and anemia, which could predispose to increased bleeding risk and larger hematoma volume.

4.1. Limitations {#sec4.1}
----------------

There are several limitations in our study. A large proportion of patients in our cohort had missing HbA1c values. The initial NIHSS Score in those patients was significantly higher than patients with documented HbA1c values. These patients also had higher in-hospital mortality and mRS at discharge. Thus, patients with missing HBA1c likely had larger, more severe ICH and there was less chance or perceived need to measure HBA1c in the hospital. These patients with missing HBA1c were more likely to have lower, not higher, random blood glucose levels which might suggest that they also had lower HBA1c levels, consistent with the findings from our analysis of those with HbA1c measured. The data are drawn from hospitals participating in GWTG-Stroke and may not apply to patients and hospitals that have different characteristics. The accuracy of the data is dependent on accurate reporting by participating sites, though good reliability of data collection has been shown in a prior paper by Xian et al [@bib27]. Even though severity of presentation could be detected from NIHSS, neither GCS nor ICH score were available for analysis. HbA1c might not accurately reflect glycemic status in the minority of patients with chronic renal insufficiency. We also did not have information regarding the degree of anemia in patients, which may be associated with lower HbA1c values and has been an independent predictor of worse ICH outcomes in other studies \[[@bib28], [@bib29]\], or the different etiologies of ICH or the cause of mortality.

5. Conclusions {#sec5}
==============

Lower HbA1c, either intentional in diabetic patients or unintentional in non-diabetic patients, in the weeks leading up to intracerebral hemorrhage is associated with poor outcomes. Further prospective studies are needed to study this effect in detail to establish any sort of cause-effect relationship.
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[^1]: HbA1c: Hemoglobin A1c, BMI: Basic Metabolic Index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, NIHSS: National Institute of Health Stroke Scale.
